Castle Biosciences (NASDAQ:CSTL – Get Free Report) and Brookdale Senior Living (NYSE:BKD – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.
Risk and Volatility
Castle Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Brookdale Senior Living has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Insider and Institutional Ownership
92.6% of Castle Biosciences shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 0.7% of Brookdale Senior Living shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Castle Biosciences and Brookdale Senior Living”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Castle Biosciences | $344.23 million | 3.04 | -$24.16 million | ($0.66) | -51.82 |
| Brookdale Senior Living | $3.19 billion | 0.81 | -$262.69 million | ($0.58) | -18.66 |
Castle Biosciences has higher earnings, but lower revenue than Brookdale Senior Living. Castle Biosciences is trading at a lower price-to-earnings ratio than Brookdale Senior Living, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Castle Biosciences and Brookdale Senior Living, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Castle Biosciences | 1 | 1 | 8 | 1 | 2.82 |
| Brookdale Senior Living | 1 | 0 | 5 | 2 | 3.00 |
Castle Biosciences presently has a consensus price target of $44.25, indicating a potential upside of 29.39%. Brookdale Senior Living has a consensus price target of $17.40, indicating a potential upside of 60.81%. Given Brookdale Senior Living’s stronger consensus rating and higher probable upside, analysts plainly believe Brookdale Senior Living is more favorable than Castle Biosciences.
Profitability
This table compares Castle Biosciences and Brookdale Senior Living’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Castle Biosciences | -5.43% | -4.15% | -3.45% |
| Brookdale Senior Living | -4.53% | -15,050.32% | -1.09% |
Summary
Brookdale Senior Living beats Castle Biosciences on 8 of the 15 factors compared between the two stocks.
About Castle Biosciences
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
About Brookdale Senior Living
Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company’s residents. This segment also operates memory care communities for residents with Alzheimer’s and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
